Sales delivered relatively in line, but the star of the show was the excellent EBIT margin of 25%, thanks to continued impressive cost contr...
Devyser reached a 25% EBIT margin and record sales, with strong operating cash flow.
Redeye presents its preview for Devyser’s Q4 2025 report, due on February 12.
Redeye’s analyst just published a Research Update on Devyser Diagnostics.
Redeye notes a somewhat mixed Q3, with a sales miss due to lower distributor sales (Thermo) and a weaker-than-expected gross margin.
Redeye presents its preview for Devyser’s Q3 2025 report, due on November 5.
Redeye comments on the now confirmed partnering with industry giant Quest Diagnostics for channel coverage of Devyser’s RHD test kit.
Redeye returns with a more in-depth take on the Q2 report.
Redeye leaves an initial comment on the strong Q2 report, where OPEX cuts and higher distributor sales (from Thermo Fisher) resulted in a po...
Redeye presents its preview for Devyser’s Q2 2025 report, due on July 22.
Redeye reiterates its base case following the company’s Q1 report.
Redeye presents its preview for Devyser’s Q1 2025 report, due on April 29.
Redeye returns with a more in-depth take on the Q4 report.
Redeye notes a substantial sales contribution from distributors, in which Thermo Fisher sales are recorded but lower-than-expected direct sa...
Redeye presents its preview for Devyser’s Q4 2024 report, due on February 13.
Redeye is impressed by the strong preliminary Q4 results, demonstrating an EBIT breakeven several quarters ahead of our anticipation.
Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day.
Redeye returns with a more in-depth take on Devyser’s Q3 report.
Redeye sees that the y/y sales are disappointing, but considering the comparable quarter and its accelerating sales prospects, we feel that ...
Redeye presents its preview for Devyser’s Q3 2024 report, due on October 30.
Redeye positively reviews the Thermo Fisher deal’s potential and the company’s US sales outlook.
Redeye sees Q2 sales in line with our forecast but higher costs, prompting us to lower our 2024e EBIT assumptions.
Redeye notes Q2 sales spot on our estimates, but an EBIT far from our expectations (though heavily impacted by transitory costs).
Redeye presents its preview for Devyser Diagnostics’ Q2 2024 report, due on July 23.
Redeye sees a quarter well in line with our estimates, and we believe that the quarterly reports will push the share the remaining c30% to o...
Redeye presents its preview for Devyser’s Q1 2024 report, which is due on May 8.
Devyser fortsätter leverera på sin tillväxtagenda och ingår nya avtal som adderar tydliga konkurrensfördelar.
Redeye missed on sales and EBIT but was positively surprised by the strong gross margin.
Kvartalet bjöd på en rekordhög tillväxt och fortsatt tydlig trend mot lönsamhet.
Q3-rapporten visar var skåpet ska stå Efter en aningen blek utveckling under Q2’23, så blev det leverans av högsta klass i det tredje kvarta...
Redeye embraces the strong sales growth in the quarter, and we emphasise the coming revenue growth drivers that should become more visible d...
Redeye is pleased to hear that Devyser’s agreement with diagnostics giant Thermo Fischer has been expanded to include Brazil.
Blandad kompott Utvecklingen under det andra kvartalet var försäljningsmässigt inte så starkt som vi hade hoppats på, medan vi överraskades ...
Redeye is encouraged by the continuing geographical expansion, and that first sales have come from the Thermo Fischer deal (in Q3), but we m...
Devyser växte med 23% i Q2 och bruttomarginalen var fortsatt stark.
Bra inledning på 2023 Året har börjat minst sagt i en positiv anda.
Redeye notes a higher OPEX than expected in the company’s Q1 report.
Tillväxtresan fortsätter och Devyser växer organiskt med 22% i Q1.
Ideal partner inom transplantationsområdet Det exklusiva samarbets- och distributionsavtal med Thermo Fisher Scientific som bolaget annonser...
Redeye embraces Devyser’s agreement with Thermo Fisher regarding its post-transplantation monitoring products.
Devyser har aviserat att de ingått ett exklusivt samarbetsavtal med Thermo Fischer Scientific.
Bra tillväxt och höga investeringar Rapporten för det fjärde kvartalet visade åter prov på den höga tillväxt som bolaget kan leverera.
Devyser lämnar ett starkt helår bakom sig och står välrustade inför ett högintressant 2023.
Redeye is positive to Devyser’s Q4 report as the company continues to deliver well on its key metrics and demonstrates a progress in line wi...
Redeye shares its preview of Devyser Diagnostics’ Q4 2022 results, due on February 21.
Upplagt för bra avslutning på 2022 Devyser har fortsatt visa hög tillväxt under hela 2022.
Devyser fortsätter att växa försäljningen i hög takt under Q3 och har aviserat ett flertal viktiga nyheter.
Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight deviation in sales and OPEX compared to...
Tydlig tillväxtprofil Devyser är ett snabbväxande diagnostikbolag med ambitionen att bli en ledande aktör inom avancerad DNA-testning som ut...
Redeye is once again positively surprised by the strong gross margin (80% Act.
Devyser levererar ett kvartal präglat av hög organisk tillväxt och tar ett viktigt kliv in på den Nordamerikanska marknaden.
Redeye is encouraged to learn that Devyser has been awarded a tender from Héma-Québec in Québec, Canada, for its non-invasive fetal RHD dete...
Analysguiden inleder bevakning av diagnostikbolaget Devyser med riktkurs 110 kronor.
Redeye regards Devyser’s Q1’22 report as strong and was surprised by the high gross margin (83%), which came in 5 pp above our estimates and...
Redeye initiates coverage of Devyser, a rapidly growing Swedish diagnostics company that offers cutting-edge test kits in oncology, heredita...
